Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Alteogen issued a corrective disclosure to adjust the scheduled acquisition date (December 31, 2024) and board resolution date (November 14, 2024) regarding its share acquisition in subsidiary Altos Biologics, following a schedule change in the intra-group merger.
📊 [Key Disclosure Details & Financial Highlights]
- Corrected Filing: Decision on Acquisition of Shares and Investment Certificates of Other Corporations (Original Filing Date: 2024-11-07)
- Reason for Correction: Amendment of schedule due to changes in the merger timeline
- Key Correction Details:
- Scheduled Acquisition Date: (Before) 2024-12-24 ☞ (After) 2024-12-31
- Board Resolution Date: (Before) 2024-11-07 ☞ (After) 2024-11-14
- Target Corporation: Altos Biologics Corp. (CEO: Hee Jeong Ji, Main Business: Pharmaceutical R&D, Subsidiary)
- Acquisition Details & Scale:
- Number of Shares to Acquire: 859,018 shares
- Acquisition Amount: KRW 31.17B (21.08% of total equity)
- Total Shares & Ownership Ratio After Acquisition: 5,859,018 shares (63.46%)
- Method & Purpose: New share acquisition / Enhancing operational efficiency through intra-group merger (Surviving: Altos Biologics, Dissolved: Alteogen Healthcare)
- Additional Notes:
- No additional cash outlay as this is a new share issuance resulting from an intra-group merger; only accounting aggregation of subsidiary investments will occur.
- Financial Summary of Target Corporation (Unit: KRW Millions):
- Current Year: Total Assets 63,427 / Total Liabilities 5,562 / Total Equity 57,864 / Capital Stock 3,472 / Net Loss -3,339
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Completion of Share Acquisition Following Revised Merger Timeline
This corrective filing reflects the postponement of the expected acquisition date to December 31, 2024, due to adjustments in the subsidiary merger schedule. Verifying whether the share acquisition and merger procedures are successfully finalized by the revised target date is important to track corporate restructuring progress. Further details can be reviewed in official subsequent filings or upcoming periodic business reports on DART.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
